Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Unternehmen & Branche
| Name | COLLEGIUM PHARMACEUTICAL, INC |
|---|---|
| Ticker | COLL |
| CIK | 0001267565 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - Specialty & Generic |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,10 Mrd. USD |
| Beta | 0,77 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 780,567,000 | 62,870,000 | 1.73 | 1,656,834,000 | 301,675,000 |
| 2025-09-30 | 10-K | 209,361,000 | 31,507,000 | 0.84 | ||
| 2025-09-30 | 10-Q | 209,361,000 | 31,507,000 | 0.84 | 1,607,328,000 | 274,808,000 |
| 2025-06-30 | 10-K | 188,000,000 | 11,983,000 | 0.34 | ||
| 2025-06-30 | 10-Q | 188,000,000 | 11,983,000 | 0.34 | 1,592,631,000 | 232,206,000 |
| 2025-03-31 | 10-Q | 177,757,000 | 2,417,000 | 0.07 | 1,631,388,000 | 234,434,000 |
| 2025-03-31 | 10-K | 177,757,000 | 2,417,000 | 0.07 | ||
| 2024-12-31 | 10-K | 181,949,000 | 12,536,000 | 0.36 | 1,663,591,000 | 228,842,000 |
| 2024-09-30 | 10-Q | 159,301,000 | 9,335,000 | 0.27 | 1,635,154,000 | 234,279,000 |
| 2024-09-30 | 10-K | 159,301,000 | 9,335,000 | 0.27 | ||
| 2024-06-30 | 10-Q | 145,276,000 | 19,606,000 | 0.52 | 1,053,388,000 | 216,583,000 |
| 2024-06-30 | 10-K | 145,276,000 | 19,606,000 | 0.52 | ||
| 2024-03-31 | 10-Q | 144,923,000 | 27,713,000 | 0.71 | 1,114,250,000 | 222,169,000 |
| 2024-03-31 | 10-K | 144,923,000 | 27,713,000 | 0.71 | ||
| 2023-12-31 | 10-K | 149,745,000 | 31,940,000 | 0.82 | 1,143,308,000 | 195,431,000 |
| 2023-09-30 | 10-K | 136,709,000 | 20,634,000 | 0.53 | ||
| 2023-09-30 | 10-Q | 136,709,000 | 20,634,000 | 0.53 | 1,177,578,000 | 178,873,000 |
| 2023-06-30 | 10-K | 135,546,000 | 13,007,000 | 0.34 | ||
| 2023-06-30 | 10-Q | 135,546,000 | 13,007,000 | 0.34 | 1,213,912,000 | 200,805,000 |
| 2023-03-31 | 10-K | 144,767,000 | -17,426,000 | -0.51 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-18 | Dieter David | Officer, EVP & General Counsel | Open Market Sale | -13,976 | 34.92 | -488,099.22 | -78,8% | |
| 2026-03-09 | Dieter David | Officer, EVP & General Counsel | Open Market Sale | -6,224 | 36.65 | -228,109.60 | -36,8% | |
| 2026-03-03 | Dreyer Scott | Officer, EVP & Chief Commercial Officer | Open Market Sale | -3,559 | 40.99 | -145,879.50 | -23,5% | |
| 2026-03-03 | Dreyer Scott | Officer, EVP & Chief Commercial Officer | Open Market Sale | -46,417 | 40.36 | -1,873,557.22 | -302,3% | |
| 2025-12-08 | Dreyer Scott | Officer, EVP & Chief Commercial Officer | Open Market Sale | -6,475 | 48.66 | -315,084.51 | -50,8% | |
| 2025-12-08 | Dreyer Scott | Officer, EVP & Chief Commercial Officer | Open Market Sale | -11,125 | 47.89 | -532,770.69 | -86,0% | |
| 2025-12-05 | Balice-Gordon Rita J. | Director | Open Market Sale | -3,650 | 47.03 | -171,673.37 | -27,7% | |
| 2025-11-12 | Fallon John A. | Director | Open Market Sale | -34,853 | 47.21 | -1,645,535.60 | -265,5% | |
| 2025-11-06 | Tupper Colleen | Officer, EVP & Chief Financial Officer | Open Market Sale | -4,858 | 41.28 | -200,516.86 | -32,4% | |
| 2025-11-06 | Tupper Colleen | Officer, EVP & Chief Financial Officer | Open Market Sale | -25,142 | 40.38 | -1,015,236.47 | -163,8% | |
| 2025-08-15 | SANTINI GINO | Director | Open Market Sale | -5,405 | 37.19 | -201,018.44 | -32,4% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.